Prognostic value of an integrated human papilloma virus and immunoscore model to predict survival in vulva squamous cell carcinoma

Rammah Elnour; Ingjerd Helstrup Hindenes; Malene Færevaag; Ingrid Benedicte Moss Kolseth; Liv Cecilie Vestrheim Thomsen; Anne Christine Johannessen; Daniela Elena Costea; Line Bjørge; Harsh Nitin Dongre

doi:10.1101/2024.09.11.24313475

Abstract

Background While the prognostic value of immune-related biomarkers is well characterized in many solid tumors, their significance in vulva squamous cell carcinoma (VSCC) remains unclear. Here, we report a comprehensive analysis of programmed death-ligand 1 (PD-L1) and immune cell infiltrates in VSCC and establish immunoscore models for classification of the disease.

Methods Archival tissues, immunohistochemistry, and digital quantification were used to investigate the number of CD4+, CD8+, CD68+, CD14+, FoxP3+, and PD-L1+ cells in epithelial and stromal compartments of VSCC (n=117). Immunoscores were developed using these parameters and applying the least absolute shrinkage and selection operator (LASSO) to identify predictors of survival. Immunoscores were integrated with HPV status, as determined by mRNA in situ hybridization, to construct internally validated nomograms. The models were assessed using Harrell’s concordance-index (c-index), calibration plots, Kaplan-Meier curves, and decision curve analysis.

Results Advanced VSCC (FIGO stage III/IV) was characterized by high numbers of CD68+ macrophages and PD-L1+ cells (Spearmans’ correlation, ρ>0.80) in the epithelium. PD-L1 status independently predicted poor progression free survival (PFS) (HR=1.80, (95% CI (1.024-3.170), p=0.041). High stromal CD68+ or CD14+ myeloid cell infiltration was associated with poor PFS and disease specific survival (DSS) (p<0.05). Immunological parameters were used to determine immunoscores. Immunoscore^PFS and immunoscore^DSS were independent prognosticators of PFS (p=0.001) and DSS (p=0.007) respectively. Integrating immunoscores with HPV status (IS-HPV index) improved the prognostic impact of the models. The c-index of IS-HPV index^PFS was 0.750 for prediction of PFS compared to 0.666 for HPV status and 0.667 for immunoscore^PFS. The c-index of IS-HPV index^DSS was 0.752 for predicting DSS compared to 0.631 for HPV status and 0.715 for immunoscore^DSS.

Conclusion In summary, an index based on HPV status and an immunoscore built on PD-L1 expression and immune cell infiltrates could potentially serve as a prognostic tool to refine risk stratification in VSCC. Further validation is warranted to demonstrate clinical utility.

WHAT IS ALREADY KNOWN ON THIS TOPIC Immunoscores have emerged as promising biomarkers in several solid tumors, however the prognostic potential of these models in vulva squamous cell carcinoma (VSCC) remains unexplored. Immunoscores are traditionally based on quantification of CD3+ and CD8+ T lymphocytes within the tumor core and invasive margin. However recent studies have highlighted the prognostic significance of additional immune cell subtypes, such as macrophages, in predicting patient survival. Advanced quantitative methods that enable the determination of immunoscores, incorporating expression of immune checkpoint proteins and infiltration of various immune cell populations within tumors, warrant further investigation.

WHAT THIS STUDY ADDS This study investigates PD-L1 expression and distinct T lymphocyte and myeloid cell subsets within the spatial architecture of VSCC to identify immunological markers with prognostic value. Computational analysis identified PD-L1+ cells, CD8+ T lymphocytes, FoxP3+ T lymphocytes, and CD14+ myeloid cells as significant survival predictors in VSCC, leading to the development of immunoscores. These immunoscores demonstrated superior predictive performance compared to the individual parameters used to construct the models. Moreover, integrating immunoscores with HPV status and constructing, for the first time, an immunoscore-HPV index nomogram enhanced the prognostic accuracy and net benefit of the models.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY The immunoscore-HPV index proposed in this study holds potential as a rapid diagnostic tool to enhance risk stratification in VSCC and facilitate the identification of patients who may benefit from less aggressive treatment approaches. Incorporating immunoscores with clinicopathological or molecular features linked to carcinogenesis in prognostic models could improve classification strategies in VSCC and other cancer types.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by The Research Council of Norway through its Centers of Excellence funding scheme (DEC, Grant No. 22325 to Center of Excellency for Cancer Biomarkers CCBIO), The Western Norway Regional Health Authority (DEC, Helse Vest Grant Nos 912260/2019 and F-13105/2024), and the Norwegian Women's Public Health Association (Grant no. 40021).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Regional Committee for Medical and Health Research Ethics Norway gave ethical approval for this work (REK Nos: 2017/279 and 2014/1907).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

Data associated with the findings of this study are included in the manuscript or in the uploaded supplementary files and are available from the corresponding author upon reasonable request.